NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in NRX Pharmaceuticals, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +7 vs. Q3 2024
- Shares held
- 1.05M
- +334.3K (+46.8%) vs. Q3 2024
- Total value
- $2.31M
- +$1.10M (+91.1%) vs. Q3 2024
- New holders
- 10
- 5 more added
- Sold out
- 3
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 47 | $47.6M |
| Q1 2026 | 33 | $13.2M |
| Q4 2025 | 28 | $14.2M |
| Q3 2025 | 24 | $13.0M |
| Q2 2025 | 25 | $9.76M |
| Q1 2025 | 22 | $4.60M |
| Q4 2024 | 25 | $2.31M |
| Q3 2024 | 18 | $1.21M |
| Q2 2024 | 19 | $1.29M |
| Q1 2024 | 31 | $1.76M |
| Q4 2023 | 30 | $1.84M |
| Q3 2023 | 34 | $964.7K |
| Q2 2023 | 32 | $4.78M |
| Q1 2023 | 30 | $2.07M |
| Q4 2022 | 33 | $3.44M |
| Q3 2022 | 30 | $3.04M |
| Q2 2022 | 37 | $2.18M |
| Q1 2022 | 34 | $25.1M |
| Q4 2021 | 38 | $12.4M |
| Q3 2021 | 23 | $16.2M |
| Q2 2021 | 18 | $18.9M |
| Q1 2021 | 1 | $4.00K |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding NRX Pharmaceuticals, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 310,314 | $682.7K | 0.13% | +180,229+138.5% | Added |
| Vanguard Group Inc | 240,316 | $528.7K | 0.00% | 00.0% | Unchanged |
| Anson Funds Management LP | 185,660 | $408.5K | 0.05% | +43,135+30.3% | Added |
| Susquehanna International Group, LLP | 82,152 | $180.7K | 0.00% | +82,152 | New |
| Geode Capital Management, LLC | 74,251 | $163.4K | 0.00% | −3,090−4.0% | Reduced |
| BlackRock, Inc. | 29,075 | $64.0K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 27,624 | $60.8K | 0.00% | +27,624 | New |
| Squarepoint Ops LLC | 25,299 | $55.7K | 0.00% | +25,299 | New |
| State Street Corp | 16,724 | $36.8K | 0.00% | 00.0% | Unchanged |
| TownSquare Capital, LLC | 15,041 | $33.1K | 0.00% | 00.0% | Unchanged |
| One Wealth Management Investment & Advisory Services, LLC | 15,041 | $33.1K | 0.05% | 00.0% | Unchanged |
| Sassicaia Capital Advisers LLC | 15,000 | $33.0K | 0.80% | +15,000 | New |
| Morgan Stanley | 4,396 | $9.67K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 3,298 | $7.25K | 0.00% | +8+0.2% | Added |
| Wells Fargo & Company | 2,160 | $4.75K | 0.00% | −500−18.8% | Reduced |
| Simplex Trading, LLC | 1,001 | $2.00K | 0.00% | +1,001 | New |
| Citigroup Inc | 593 | $1.30K | 0.00% | +593 | New |
| UBS Group AG | 150 | $330 | 0.00% | +112+294.7% | Added |
| FMR LLC | 150 | $330 | 0.00% | +150 | New |
| Group One Trading, L.P. | 99 | $218 | 0.00% | +99 | New |
| Advisor Group Holdings, Inc. | 90 | $198 | 0.00% | +90 | New |
| GWM Advisors LLC | 83 | $183 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 53 | $117 | 0.00% | +3+6.0% | Added |
| Carolina Wealth Advisors, LLC | 50 | $110 | 0.00% | +50 | New |
| Larson Financial Group LLC | 22 | $48 | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 0 | $0 | 0.00% | −35,049−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −2,544−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −47−100.0% | Sold out |